Clinical trials on Primary Myelofibrosis

Primary Myelofibrosis (PMF) is a rare type of bone marrow cancer that disrupts the body’s normal production of blood cells. This disease is characterized by the replacement of the bone marrow’s blood-forming cells with scar tissue, leading to a deficiency in the production of normal blood cells. Patients with PMF often experience symptoms like fatigue, weakness, and abdominal discomfort due to an enlarged spleen, as the spleen and liver attempt to compensate for the bone marrow’s reduced function.


  • Anemia: Reduced red blood cell production causes fatigue, weakness, and shortness of breath.
  • Thrombocytopenia: Low platelet counts lead to increased bleeding and bruising, posing risks during surgeries or injuries.
  • Splenomegaly: Enlargement of the spleen can cause abdominal pain and fullness, interfering with daily activities and eating.
  • Increased risk of infections: Impaired immune function due to abnormal white blood cell production increases susceptibility to infections.
  • Transformation to acute myeloid leukemia (AML): There is a risk of the disease progressing to a more aggressive form of leukemia, affecting long-term survival.
  • Bone pain and osteosclerosis: Changes in bone marrow structure can lead to bone pain and hardening.
  • Cardiovascular complications: Increased risk of blood clots, including deep vein thrombosis and pulmonary embolism, due to abnormal blood cell counts.

Treatment Methods

  • Janus Kinase (JAK) inhibitors: Ruxolitinib is a commonly prescribed treatment that helps reduce spleen size and alleviate symptoms.
  • Allogeneic stem cell transplantation: The only potentially curative treatment, suitable primarily for younger patients with severe disease.
  • Androgen therapy and corticosteroids: Used to manage anemia and other blood cell deficiencies.
  • Blood transfusions: Employed to address severe anemia and improve the patient’s quality of life.
  • Hydroxyurea: Often used to control high blood cell counts and reduce the risk of thrombosis.


The prognosis for patients with Primary Myelofibrosis varies widely based on factors such as age, disease severity, and response to treatment. Without treatment, the disease typically progresses, leading to worsening symptoms and a decreased quality of life due to complications such as severe anemia and increased infection risk. With treatment, especially with JAK inhibitors and proper management of symptoms, many patients experience significant improvement in their quality of life and symptom control. The only curative approach remains allogeneic stem cell transplantation, which is not suitable for all patients due to its associated risks. Generally, PMF has a chronic and progressive course, and ongoing medical care is essential to manage its complications and improve patient outcomes.